News & Media

Recent updates from Arcutis.

July 13, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

June 22, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

June 10, 2020

Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference

June 1, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

May 27, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

May 12, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

April 27, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

April 21, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

March 23, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

March 16, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

March 5, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

March 3, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download